Cdk2/9 Inhibitor is a cell-permeable aminopyrimidinyl compound that acts as a potent and ATP-competitive inhibitor of Cdk2/E and Cdk9/T1. Also inhibits GSK-3β, Cdk4/D, Cdk7/H, Cdk1/B, and Abl at higher concentrations, but exhibits little activity towards 9 other kinases. Cdk2/9 Inhibitor has been shown to inhibit phosphorylation of cellular Cdk substrates, pRb and RNA polymerase II, and Cdk2-mediated S-phase transition.
1. Wang, Shudong., et al., 2004. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. Journal of medicinal chemistry. 47(7): 1662-75. PMID: 15027857
2. Kontopidis, George., et al., 2006. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chemistry & biology. 13(2): 201-11. PMID: 16492568
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.